Dronedarone successfully maintains sinus rhythm in patients with atrial fibrillation
This article has no abstract so we have provided the first paragraph of the full text.
Amiodarone is an effective antiarrhythmic agent, but it can have potentially serious adverse effects. Two identical multicenter trials were conducted to assess the efficacy of dronedarone, a potential alternative to amiodarone, for maintaining sinus rhythm in patients with atrial fibrillation (AF) or flutter. In total, 409 patients were randomized to placebo and 828 to dronedarone (400 mg orally twice daily). The mean age of participants was 63 years.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
